Stock Screener
Show:
Sort
Country
Sector
Risk rating
1
2
3
4
5
6
7
Risk factors
Default risk
1
2
3
4
5
6
7
Volatility
1
2
3
4
5
6
7
Stress test
1
2
3
4
5
6
7
Selling difficulty
1
2
3
4
5
6
7
Country risks
1
2
3
4
5
6
7
Other risks
1
2
3
4
5
6
7
Profitability factors
Valuation
1
2
3
4
5
6
7
Analyst view
1
2
3
4
5
6
7
Performance
1
2
3
4
5
6
7
Profitability
1
2
3
4
5
6
7
Growth
1
2
3
4
5
6
7
Dividends
1
2
3
4
5
6
7
Results: 23
Novo Nordisk A/S
NOVO-B.COAscendis Pharma A/S
ASNDGenmab A/S
GMAB.COColoplast A/S
COLO-B.COZealand Pharma A/S
ZEAL.CODemant A/S
DEMANT.COGN Store Nord A/S
GN.COAmbu A/S
AMBU-B.COBavarian Nordic A/S
BAVA.COALK-Abello A/S
ALK-B.COH. Lundbeck A/S
HLUN-B.COChemoMetec A/S
CHEMM.COGubra A/S
GUBRA.COSaniona AB (publ)
SANION.STEvaxion A/S
EVAXBioPorto A/S
BIOPOR.COStenocare A/S
STENO.COFluoGuide A/S
FLUO.STScandinavian Medical Solutions A/S
SMSMED.COInitiator Pharma A/S
INIT.STPharma Equity Group A/S
PEG.COViroGates A/S
VIRO.COMonsenso A/S
MONSO.CO
Return for Q2 2026:14.99%
Portfolio composition:
Return for Q2 2026:8.38%
Portfolio composition: